Quarterly Activity Report and Appendix 4C for Q3 FY2025
Filed with ASX · · 12 pages · English
Summary by 6ix AI
The report highlights a substantial increase in operating revenue year-to-date, alongside a successful cost reduction program that has already achieved notable savings. Additionally, the company is nearing completion of its regulatory submission for a key product, CT:VQ™, which has garnered interest from major medical institutions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- Supplementary Prospectus
- 4DMedical converts Integral Diagnostics pilot into contract
- 4DMedical wins industry partners and discussed in Congress
- Cost reduction program delivers $6.5m in annualised savings
- Prospectus
Later from 4DMedical
- 4DMedical wins commercial contract with Intermountain Health
- 4DMedical files FDA submission for CTVQ
- Investor Presentation - FDA Submission for CTVQ
- Olympus launches new SeleCT Screening campaign
- 4DMedical contract with Stanford, includes CTVQ
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical